A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of Efficacy and Safety of Asenapine Compared with Placebo Using Haloperidol Positive Control in Subjects with an Acute Exacerbation of Schizophrenia

Trial Profile

A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of Efficacy and Safety of Asenapine Compared with Placebo Using Haloperidol Positive Control in Subjects with an Acute Exacerbation of Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Asenapine (Primary) ; Haloperidol
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms HERA
  • Sponsors Organon
  • Most Recent Events

    • 31 Oct 2013 Last checked against ClinicalTrials.gov record (extension study NCT00156065).
    • 31 Oct 2013 Last checked against ClinicalTrials.gov record (extension study NCT00156065).
    • 16 Sep 2009 Results of the extension study have been presented at ECNP 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top